Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm study of human coagulation factor IX for on-demand treatment in moderate to severe hemophilia B
CTR20240499Phase 3Completed
- Sponsor
- Hualan Biological Engineering Inc.
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human coagulation factor IX in hemophilia B (HB), sponsored by Hualan Biological Engineering Inc.. Started Mar 2024; status: completed.
02
Drugs
human coagulation factor IX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20240499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240499.